Teachers Advisors LLC increased its stake in shares of The Medicines Company (NASDAQ:MDCO) by 1.0% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 392,208 shares of the company’s stock after buying an additional 3,834 shares during the period. Teachers Advisors LLC’s holdings in The Medicines Company were worth $19,179,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. FMR LLC boosted its stake in The Medicines Company by 0.8% in the first quarter. FMR LLC now owns 10,707,056 shares of the company’s stock valued at $523,575,000 after buying an additional 87,958 shares in the last quarter. Iridian Asset Management LLC CT boosted its stake in The Medicines Company by 218.7% in the first quarter. Iridian Asset Management LLC CT now owns 3,022,681 shares of the company’s stock valued at $147,809,000 after buying an additional 2,074,261 shares in the last quarter. Norges Bank bought a new stake in The Medicines Company during the fourth quarter valued at approximately $22,599,000. Frontier Capital Management Co. LLC boosted its stake in The Medicines Company by 139.9% in the first quarter. Frontier Capital Management Co. LLC now owns 604,020 shares of the company’s stock valued at $29,537,000 after buying an additional 352,230 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its stake in The Medicines Company by 7.5% in the fourth quarter. Macquarie Group Ltd. now owns 599,604 shares of the company’s stock valued at $20,351,000 after buying an additional 41,994 shares in the last quarter.

The Medicines Company (NASDAQ MDCO) opened at 38.70 on Friday. The company has a 50-day moving average price of $40.22 and a 200 day moving average price of $44.14. The Medicines Company has a 12 month low of $30.80 and a 12 month high of $55.95. The stock’s market capitalization is $2.75 billion.

The Medicines Company (NASDAQ:MDCO) last issued its quarterly earnings results on Wednesday, April 26th. The company reported ($1.44) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by $0.31. The business had revenue of $24.20 million during the quarter, compared to analyst estimates of $37.76 million. The Medicines Company had a negative net margin of 91.25% and a negative return on equity of 19.09%. The company’s revenue was down 51.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.03) earnings per share. Equities analysts predict that The Medicines Company will post ($5.97) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Teachers Advisors LLC Buys 3,834 Shares of The Medicines Company (MDCO)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/teachers-advisors-llc-buys-3834-shares-of-the-medicines-company-mdco/1441304.html.

Several equities research analysts recently commented on MDCO shares. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of The Medicines Company in a report on Monday, March 20th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $62.00 price target on shares of The Medicines Company in a report on Wednesday, April 12th. ValuEngine raised The Medicines Company from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Cowen and Company increased their price target on The Medicines Company from $39.00 to $61.00 and gave the company an “outperform” rating in a report on Wednesday, April 19th. Finally, CIBC set a $50.00 price target on The Medicines Company in a report on Tuesday, May 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. The Medicines Company presently has an average rating of “Buy” and an average target price of $54.40.

About The Medicines Company

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).

Institutional Ownership by Quarter for The Medicines Company (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with Analyst Ratings Network's FREE daily email newsletter.